Over the last year, diabetes technology saw significant changes, including the acceleration of patch pumps, ever-smaller continuous glucose monitors (CGM), implanted CGMs and increased interest in ...

Zenas Biopharma Inc.’s positive data from the phase III Indigo trial with obexelimab in immunoglobulin G4-related disease (IgG4-RD) set investigators to speculating about the bifunctional antibody’s ...

December 2025 was a big month for announcements from Psithera Inc. The Watertown, Mass.-based newco announced its name change ...

Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, ...

Four optimization trends dominated the med-tech industry in 2025. Growth-driven acquisitions propelled major players into hot ...

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate ...

Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the ...

The U.S. FDA recently cleared Medtronic plc’s Hugo robotic-assisted surgery system and CMR Surgical Ltd.’s Versius Plus ...

After a volatile but ultimately strong year for biopharma stocks, 2025 delivered a mixed picture marked by sharp workforce reductions alongside resilient capital markets and high-value dealmaking.

In a recent publication in Molecular Therapy, researchers from Drexel University College of Medicine and UMass Chan Medical ...

BioWorld logged 170 clinical trial updates across phases I through III in November 2025, a decline from 252 updates in ...